Concert Pharmaceuticals, Inc.
Deuterated GFT-505

Last updated:

Abstract:

This invention relates to novel deuterated forms of GFT-505, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are characterized by reduced PPAR-alpha and/or PPAR-delta activity.

Status:
Grant
Type:

Utility

Filling date:

16 Feb 2017

Issue date:

15 Oct 2019